Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT06970951 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Rheumatoid Arthritis
Dry Syndrome
Idiopathic Inflammatory Myopathies
Systemic Sclerosis

Interventions

BIOLOGICAL: UTAA91 injection

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.